ANGPTL3 Inhibitors

Why This Matters

Most lipid-lowering therapies work by increasing LDL receptor activity. ANGPTL3 inhibitors represent a fundamentally different approach. Rather than targeting cholesterol synthesis, absorption, or LDL receptor recycling, they enhance the body's ability to metabolize triglyceride-rich lipoproteins. This mechanism lowers triglycerides, remnant lipoproteins, ApoB, and LDL cholesterol, offering an important therapeutic option for selected patients with severe dyslipidemia.

What Is ANGPTL3?

Angiopoietin-like protein 3 (ANGPTL3) is a protein produced almost exclusively by the liver.

Its principal function is to inhibit lipoprotein lipase (LPL) and endothelial lipase, two enzymes responsible for the metabolism of triglyceride-rich lipoproteins. By acting as a physiological brake on these enzymes, ANGPTL3 slows the clearance of triglyceride-rich particles from the circulation.

How ANGPTL3 Works

Under normal conditions, lipoprotein lipase hydrolyzes triglycerides contained within chylomicrons and VLDL, releasing free fatty acids for storage or energy production.

When ANGPTL3 is inhibited, lipoprotein lipase functions more efficiently, accelerating the metabolism of chylomicrons and VLDL, reducing remnant lipoproteins, and lowering circulating triglycerides.

In many patients, ApoB and LDL cholesterol also decline, although the magnitude of LDL reduction varies among different patient populations.

Lessons from Human Genetics

The importance of ANGPTL3 became evident through studies of individuals with naturally occurring loss-of-function mutations.

These individuals have lifelong reductions in triglycerides, LDL cholesterol, and HDL cholesterol, yet experience substantially lower rates of atherosclerotic cardiovascular disease — the same pattern of evidence, a natural genetic experiment rather than a randomized trial, that supports the PCSK9 story in Chapter 14.

ANGPTL3 Inhibitors

Evinacumab is the first approved ANGPTL3 inhibitor. It is a fully human monoclonal antibody that binds circulating ANGPTL3, preventing it from inhibiting lipoprotein lipase and endothelial lipase.

Unlike statins, ezetimibe, and PCSK9 inhibitors, evinacumab can lower LDL cholesterol even in patients with little or no functional LDL receptor activity. This makes it particularly valuable for patients with homozygous familial hypercholesterolemia.

Additional therapies targeting ANGPTL3, including RNA-based approaches, are currently under clinical investigation.

Clinical Benefits

ANGPTL3 inhibition produces marked reductions in triglycerides and remnant lipoproteins while also lowering ApoB and LDL cholesterol in many patients.

Its greatest clinical value currently lies in patients with homozygous familial hypercholesterolemia and selected individuals with severe refractory dyslipidemia. In the pivotal trial that led to its approval, evinacumab lowered LDL cholesterol by roughly 49 percent at four weeks in patients with homozygous familial hypercholesterolemia who were already on other lipid-lowering therapy — a population in which statins and PCSK9 inhibitors often do very little, because both depend on LDL receptor function that many of these patients largely lack. That dependence-free mechanism, not raw potency, is what makes evinacumab clinically distinct rather than simply another add-on drug. It is currently approved specifically for this narrow, severe, genetically defined population, not for common hypercholesterolemia.

Safety and Tolerability

Clinical experience with ANGPTL3 inhibitors remains more limited than with statins or PCSK9 inhibitors.

Available data suggest that evinacumab is generally well tolerated. The most commonly reported adverse effects include infusion-related reactions, nasopharyngitis, and influenza-like symptoms.

Clinical Pearls

• ANGPTL3 inhibits lipoprotein lipase and endothelial lipase.
• Blocking ANGPTL3 accelerates clearance of triglyceride-rich lipoproteins.
• ANGPTL3 inhibition lowers triglycerides, remnant lipoproteins, ApoB, and often LDL cholesterol.
• Evinacumab remains effective even when LDL receptor function is severely impaired.
• ANGPTL3 inhibition represents a mechanism distinct from statins, ezetimibe, and PCSK9 inhibitors.

Common Misconceptions

Misconception: ANGPTL3 inhibitors work by increasing LDL receptor activity.

Reality: Their primary mechanism is enhancing the metabolism of triglyceride-rich lipoproteins through increased lipoprotein lipase activity.

Misconception: ANGPTL3 inhibitors are simply another type of PCSK9 inhibitor.

Reality: These therapies target entirely different biological pathways and have different clinical applications.

Misconception: ANGPTL3 inhibitors are appropriate for all patients with elevated LDL cholesterol.

Reality: Their current role is primarily in selected patients with severe genetic dyslipidemias or refractory hyperlipidemia, while broader indications continue to be studied.

Clinical Bottom Line

ANGPTL3 inhibitors introduce a strategy for treating dyslipidemia by enhancing the metabolism of triglyceride-rich lipoproteins rather than increasing LDL receptor activity. Their ability to lower triglycerides, remnant lipoproteins, ApoB, and LDL cholesterol — particularly in patients with severely impaired LDL receptor function — makes them an important addition to modern lipid-lowering therapy.